Marshall Wace, LLP Pro Qr Therapeutics N.V. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.15 - $2.21 $54,776 - $105,266	-47,632 Reduced 82.53%	10,085 $19,000
Q3 2023 Nov 14, 2023	SELL	$1.3 - $1.77 $327,264 - $445,583	-251,742 Reduced 81.35%	57,717 $75,000
Q2 2023 Aug 14, 2023	SELL	$1.62 - $2.32 $514,296 - $736,523	-317,467 Reduced 50.64%	309,459 $501,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $410,558 - $755,098	206,311 Added 49.05%	626,926 $1.34 Million
Q4 2022 Feb 14, 2023	BUY	$0.8 - $3.7 $277,748 - $1.28 Million	347,185 Added 472.81%	420,615 $1.56 Million
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $72,329 - $86,990	-97,742 Reduced 57.1%	73,430 $55,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $95,856 - $171,172	171,172 New	171,172 $133,000
Q2 2021 Aug 13, 2021	SELL	$5.75 - $7.59 $1.83 Million - $2.41 Million	-317,705 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.14 - $9.22 $1.32 Million - $2.93 Million	317,705 New	317,705 $2.1 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $157M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.